anti-CD93 antibody

Montis Biosciences is developing a monoclonal antibody targeting CD93, a C-type lectin-like transmembrane protein primarily expressed on vascular endothelial cells. CD93 is involved in tumor angiogenesis and inflammation, particularly in the perivascular space. By inhibiting CD93, the antibody aims to normalize tumor vasculature and potentially enhance anti-tumor immune responses. This program is specifically focused on lung squamous cell carcinoma (LUSC), an underserved oncology indication driven by inflammation. As of early 2026, a lead candidate has been selected and the program is in the preclinical stage, with the company seeking a partner for further development.

Other names

anti-CD93 monoclonal antibodyanti-CD-93 monoclonal antibodyanti-CD 93 monoclonal antibodyCD93 antibodyCD-93 antibodyCD 93 antibody